-
1
-
-
77950988234
-
Infliximab, azathioprine, or combination therapy for crohn's disease
-
Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for crohn's disease. N Engl J Med 2010, 362:1383-1395.
-
(2010)
N Engl J Med
, vol.362
, pp. 1383-1395
-
-
Colombel, J.F.1
Sandborn, W.J.2
Reinisch, W.3
-
2
-
-
80455139421
-
Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial
-
Panccione R., Ghosh S., Middleton S., et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC success trial. Gastroenterology 2011, 140:S-134.
-
(2011)
Gastroenterology
, vol.140
, pp. S-134
-
-
Panccione, R.1
Ghosh, S.2
Middleton, S.3
-
3
-
-
84885618122
-
The management of immunosuppression in patients with inflammatory bowel disease and cancer
-
Bernheim O., Colombel J.F., Ullman T.A., et al. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013, 62:1523-1528.
-
(2013)
Gut
, vol.62
, pp. 1523-1528
-
-
Bernheim, O.1
Colombel, J.F.2
Ullman, T.A.3
-
4
-
-
33748987908
-
Cancer despite immunosurveillance: immunoselection and immunosubversion
-
Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6:715-727.
-
(2006)
Nat Rev Immunol
, vol.6
, pp. 715-727
-
-
Zitvogel, L.1
Tesniere, A.2
Kroemer, G.3
-
5
-
-
56949101640
-
Immune escape by epstein-barr virus associated malignancies
-
Munz C., Moormann A. Immune escape by epstein-barr virus associated malignancies. Semin Cancer Biol 2008, 18:381-387.
-
(2008)
Semin Cancer Biol
, vol.18
, pp. 381-387
-
-
Munz, C.1
Moormann, A.2
-
6
-
-
24944519200
-
Azathioprine and UVA light generate mutagenic oxidative DNA damage
-
O'Donovan P., Perrett C.M., Zhang X., et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005, 309:1871-1874.
-
(2005)
Science
, vol.309
, pp. 1871-1874
-
-
O'Donovan, P.1
Perrett, C.M.2
Zhang, X.3
-
7
-
-
84857801058
-
Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?
-
Beaugerie L. Inflammatory bowel disease therapies and cancer risk: where are we and where are we going?. Gut 2012, 61:476-483.
-
(2012)
Gut
, vol.61
, pp. 476-483
-
-
Beaugerie, L.1
-
8
-
-
0842281645
-
Cell death: critical control points
-
Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
-
(2004)
Cell
, vol.116
, pp. 205-219
-
-
Danial, N.N.1
Korsmeyer, S.J.2
-
9
-
-
0034641918
-
The biochemistry of apoptosis
-
Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
-
(2000)
Nature
, vol.407
, pp. 770-776
-
-
Hengartner, M.O.1
-
10
-
-
67349162130
-
Tumour necrosis factor and cancer
-
Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9:361-371.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 361-371
-
-
Balkwill, F.1
-
11
-
-
0034764110
-
Inflammatory bowel disease is not associated with an increased risk of lymphoma
-
Lewis J.D., Bilker W.B., Brensinger C., et al. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001, 121:1080-1087.
-
(2001)
Gastroenterology
, vol.121
, pp. 1080-1087
-
-
Lewis, J.D.1
Bilker, W.B.2
Brensinger, C.3
-
12
-
-
0032754121
-
Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine
-
Korelitz B.I., Mirsky F.J., Fleisher M.R., et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999, 94:3248-3253.
-
(1999)
Am J Gastroenterol
, vol.94
, pp. 3248-3253
-
-
Korelitz, B.I.1
Mirsky, F.J.2
Fleisher, M.R.3
-
13
-
-
0033795223
-
Increased incidence of non-hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low
-
Farrell R.J., Ang Y., Kileen P., et al. Increased incidence of non-hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000, 47:514-519.
-
(2000)
Gut
, vol.47
, pp. 514-519
-
-
Farrell, R.J.1
Ang, Y.2
Kileen, P.3
-
14
-
-
78650239266
-
A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease
-
Kotlyar D.S., Osterman M.T., Diamond R.H., et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2011, 9:36-41.e1.
-
(2011)
Clin Gastroenterol Hepatol
, vol.9
, pp. 36-41.e1
-
-
Kotlyar, D.S.1
Osterman, M.T.2
Diamond, R.H.3
-
15
-
-
77349117814
-
Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease
-
Long M.D., Herfarth H.H., Pipkin C.A., et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2010, 8:268-274.
-
(2010)
Clin Gastroenterol Hepatol
, vol.8
, pp. 268-274
-
-
Long, M.D.1
Herfarth, H.H.2
Pipkin, C.A.3
-
16
-
-
84864225717
-
Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease
-
Long M.D., Martin C.F., Pipkin C.A., et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012, 143:390-399.
-
(2012)
Gastroenterology
, vol.143
, pp. 390-399
-
-
Long, M.D.1
Martin, C.F.2
Pipkin, C.A.3
-
17
-
-
80054862378
-
Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease
-
e1-e5
-
Peyrin-Biroulet L., Khosrotehrani K., Carrat F., et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011, 141:1621-1628. e1-e5.
-
(2011)
Gastroenterology
, vol.141
, pp. 1621-1628
-
-
Peyrin-Biroulet, L.1
Khosrotehrani, K.2
Carrat, F.3
-
18
-
-
77954426838
-
Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study
-
Armstrong R.G., West J., Card T.R. Risk of cancer in inflammatory bowel disease treated with azathioprine: a UK population-based case-control study. Am J Gastroenterol 2010, 105:1604-1609.
-
(2010)
Am J Gastroenterol
, vol.105
, pp. 1604-1609
-
-
Armstrong, R.G.1
West, J.2
Card, T.R.3
-
19
-
-
22644446331
-
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
-
Kandiel A., Fraser A.G., Korelitz B.I., et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121-1125.
-
(2005)
Gut
, vol.54
, pp. 1121-1125
-
-
Kandiel, A.1
Fraser, A.G.2
Korelitz, B.I.3
-
20
-
-
42449097149
-
Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study
-
Sogaard K.K., Cronin-Fenton D.P., Pedersen L., et al. Survival in Danish patients with breast cancer and inflammatory bowel disease: a nationwide cohort study. Inflamm Bowel Dis 2008, 14:519-525.
-
(2008)
Inflamm Bowel Dis
, vol.14
, pp. 519-525
-
-
Sogaard, K.K.1
Cronin-Fenton, D.P.2
Pedersen, L.3
-
21
-
-
84905581315
-
Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer
-
Beaugerie L., Carrat F., Colombel J.F., et al. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 2014, 63:1416-1423.
-
(2014)
Gut
, vol.63
, pp. 1416-1423
-
-
Beaugerie, L.1
Carrat, F.2
Colombel, J.F.3
-
22
-
-
0027412956
-
The effect of immunosuppression on pre-existing cancers
-
Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993, 55:742-747.
-
(1993)
Transplantation
, vol.55
, pp. 742-747
-
-
Penn, I.1
-
23
-
-
77953103015
-
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the british society for rheumatology biologics register
-
Dixon W.G., Watson K.D., Lunt M., et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the british society for rheumatology biologics register. Arthritis Care Res (Hoboken) 2010, 62:755-763.
-
(2010)
Arthritis Care Res (Hoboken)
, vol.62
, pp. 755-763
-
-
Dixon, W.G.1
Watson, K.D.2
Lunt, M.3
-
24
-
-
77955479672
-
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the german biologics register RABBIT
-
Strangfeld A., Hierse F., Rau R., et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the german biologics register RABBIT. Arthritis Res Ther 2010, 12:R5.
-
(2010)
Arthritis Res Ther
, vol.12
, pp. R5
-
-
Strangfeld, A.1
Hierse, F.2
Rau, R.3
-
25
-
-
34249908092
-
Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review
-
Gutierrez-Dalmau A., Campistol J.M. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Drugs 2007, 67:1167-1198.
-
(2007)
Drugs
, vol.67
, pp. 1167-1198
-
-
Gutierrez-Dalmau, A.1
Campistol, J.M.2
-
26
-
-
84904466334
-
Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease
-
Rajca S., Seksik P., Bourrier A., et al. Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. J Crohns Colitis 2014, 8:819-824.
-
(2014)
J Crohns Colitis
, vol.8
, pp. 819-824
-
-
Rajca, S.1
Seksik, P.2
Bourrier, A.3
-
27
-
-
84865312684
-
Effects of cancer treatment on inflammatory bowel disease remission and reactivation
-
Axelrad J.E., Fowler S.A., Friedman S., et al. Effects of cancer treatment on inflammatory bowel disease remission and reactivation. Clin Gastroenterol Hepatol 2012, 10:1021-1027.
-
(2012)
Clin Gastroenterol Hepatol
, vol.10
, pp. 1021-1027
-
-
Axelrad, J.E.1
Fowler, S.A.2
Friedman, S.3
|